RUZZO, ANNAMARIA
 Distribuzione geografica
Continente #
NA - Nord America 107
EU - Europa 91
AS - Asia 31
SA - Sud America 5
AF - Africa 2
OC - Oceania 1
Totale 237
Nazione #
US - Stati Uniti d'America 105
IT - Italia 39
DE - Germania 13
NL - Olanda 9
HK - Hong Kong 7
CZ - Repubblica Ceca 6
EC - Ecuador 5
FI - Finlandia 5
FR - Francia 4
IL - Israele 4
KR - Corea 4
VN - Vietnam 4
IE - Irlanda 3
RU - Federazione Russa 3
UA - Ucraina 3
AT - Austria 2
IQ - Iraq 2
JP - Giappone 2
SE - Svezia 2
TH - Thailandia 2
TR - Turchia 2
TW - Taiwan 2
ZA - Sudafrica 2
AU - Australia 1
CA - Canada 1
CH - Svizzera 1
CN - Cina 1
GB - Regno Unito 1
IN - India 1
MX - Messico 1
Totale 237
Città #
Urbino 19
Ashburn 10
Santa Cruz 10
Fairfield 9
Seattle 7
Chicago 5
Cotacachi 5
Helsinki 5
Des Moines 4
Dong Ket 4
Houston 4
Tel Aviv 4
Ansan-si 3
Cambridge 3
Central 3
Dublin 3
Milan 3
Reutlingen 3
Baghdad 2
Bangkok 2
Boston 2
Buffalo 2
Dallas 2
Denizli 2
Heidelberg 2
Las Vegas 2
Nashville 2
New Taipei 2
Paris 2
Pisa 2
Rome 2
Rotterdam 2
Stockholm 2
The Hague 2
Vienna 2
Amsterdam 1
Ancona 1
Ascea 1
Barnala 1
Boardman 1
Bremen 1
Bridgeville 1
Brno 1
Camponogara 1
Cape Town 1
Clearwater 1
Columbus 1
Como 1
Coram 1
Denver 1
East White Plains 1
Erba 1
Guadalajara 1
Higashiikebukuro 1
Los Angeles 1
Marsala 1
Monopoli 1
Moscow 1
Mount Marshall 1
Nagoya 1
Namyangju 1
New York 1
Nuremberg 1
Palermo 1
Piacenza 1
Portland 1
Prague 1
Redmond 1
Saint Petersburg 1
San Diego 1
San Francisco 1
Sandy 1
St. Gallen 1
Stezzano 1
Toronto 1
Toulouse 1
Turin 1
Utrecht 1
Verneuil-sur-Seine 1
Wilmington 1
Woodbridge 1
Totale 184
Nome #
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition., file 0931cea8-f5b9-4891-86aa-da8bc21ae38a 99
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma, file e18b865d-6443-1ee6-e053-3a05fe0ae544 56
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomized, phase III adjuvant TOSCA trial in high-risk colon cancer patients., file e18b865c-3efb-1ee6-e053-3a05fe0ae544 52
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan, file e18b865b-81d6-1ee6-e053-3a05fe0ae544 11
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy, file e18b865c-8ecb-1ee6-e053-3a05fe0ae544 11
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib, file e18b865d-8d7f-1ee6-e053-3a05fe0ae544 3
Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC), file e18b865b-d2ef-1ee6-e053-3a05fe0ae544 2
Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial, file e18b865c-65fb-1ee6-e053-3a05fe0ae544 2
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy., file e18b865c-913e-1ee6-e053-3a05fe0ae544 1
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer., file e18b865c-9a4f-1ee6-e053-3a05fe0ae544 1
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer, file e18b865d-68fe-1ee6-e053-3a05fe0ae544 1
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition., file e18b865d-8954-1ee6-e053-3a05fe0ae544 1
Totale 240
Categoria #
all - tutte 925
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 925


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208 3 5 0 0 0 0 0 0 0 0 0 0
2020/202121 0 0 0 0 0 0 0 0 0 12 0 9
2021/202244 0 3 2 2 2 0 3 1 0 2 13 16
2022/2023109 7 0 20 16 7 13 15 3 5 8 10 5
2023/202458 0 2 11 7 12 12 7 2 1 3 1 0
Totale 240